Searched for
PEPTIDE THERAPEUTICS MARKET
For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 DiabetesDr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to rece...
- Granules India shares in focus on acquiring Swiss firm for Rs 192 crGranules India has acquired Swiss CDMO company Senn Chemicals AG for Rs 192 crore, expanding its peptide therapeutics market presence. The ...
- Alembic Pharma gets USFDA nod for generic injection to treat hereditary angioedemaThe approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) for Icatibant injection of str...
- Top stock to buy: Aurobindo Pharma has returned a whopping 126.3% in one yearAnalysts are bullish on Aurobindo Pharma due to the buoyant growth prospects of pharma industry and the company’s strong strategic investme...
- Enzene Biosciences raises $50 million to expand ops in India, US marketsIn a press statement, Enzene said it would leverage the fresh funds to enhance its manufacturing capabilities and drive expansion in its co...
- This stock surged 650% last year, and drew marquee investors like Dolly Khanna in Q4Apart from Dolly Khanna, Mukul Agrawal, another renowned value investor, increased his holding in the company to 2.34 per cent from 1.95 pe...
- Aurobindo Pharma targets a revenue of over $3 billion by 2017-18Aurobindo Pharma is targeting a revenue of over $3 billion (over Rs 19,800 crore) by 2017-18 and plans to expand its basket with drugs to t...
- Aurobindo Pharma to expand product basket; eyes $3 billion revenues by FY18Aurobindo is targetting a revenue of over $ 3 billion by 2017-18 and plans to expand its basket with new drugs to treat cancer.
- Indian scientist develops potential non-insulin diabetes drugArnab De, a PhD in Microbiology and Immunology from Columbia University, has developed the non-insulin drug candidate in collaboration with...
- Strides Arcolabs looks to seal more drug supply deals with global pharma cosStrides Acrolabs is discussing drug supply deal for niche therapeutics areas with global drug pharma companies.
- Biocon joins hands with US co Amylin for diabetes drugBiocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals.
- Indian drug cos prepare a peptide mixAs blockbuster drugs are set to lose exclusivity in the US, Indian pharma companies are gearing up to tap the fast-growing generic peptide ...
Load More
